Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Drug Policy ; 74: 1-10, 2019 12.
Article in English | MEDLINE | ID: mdl-31382201

ABSTRACT

BACKGROUND: Recreational cannabis has been legalized in 11 states and Washington DC in the US. However, little is known about individual preferences for legal cannabis products. This study estimated the impacts of tetrahydrocannabinol (THC), cannabidiol (CBD), warning messages, and price on preferences for cannabis flowers. METHODS: A cross-sectional online survey with discrete choice experiments was implemented in October 2017. A sample of 2400 adults aged 21 years or older were recruited from 6 US states with recreational cannabis legalization, consisting of 1200 past-year nonusers and 1200 past-year users. Each respondent was randomly assigned to 12 discrete choice scenarios, each asking them to choose from an opt-out option and 3 cannabis flower products with varying levels in THC, CBD, warning messages, and price. The impacts of product attributes on individual choices were analyzed with nested logit regressions. RESULTS: Both cannabis nonusers and users preferred higher CBD and lower price. Users also preferred higher THC. The results on warning messages were mixed: graphic warning on drugged driving and text warning message had positive impacts on nonusers' and users' preferences for cannabis flowers, respectively, whereas FDA disapproval disclaimer had negative impacts on nonusers' preferences. Heterogeneities in preferences were revealed among nonusers by former use status and among users by reason of use. Particularly, medical cannabis users were not as responsive to THC as recreational cannabis users or dual users were. Regarding relative importance of the attributes, all respondents but medical cannabis users perceived price as the most important attribute (relative importance 51-64%), whereas medical cannabis users perceived CBD as the most important attribute (relative importance 47%). CONCLUSION: The findings indicated that product characteristics may have influences on US adults' choices of legal cannabis flower products and may deserve consideration for cannabis regulatory framework.


Subject(s)
Cannabidiol/supply & distribution , Commerce/statistics & numerical data , Dronabinol/supply & distribution , Marijuana Smoking/economics , Adult , Cannabidiol/economics , Cannabis/chemistry , Choice Behavior , Commerce/legislation & jurisprudence , Cross-Sectional Studies , Dronabinol/economics , Female , Flowers , Humans , Legislation, Drug , Male , Marijuana Smoking/epidemiology , Medical Marijuana/economics , Medical Marijuana/supply & distribution , Middle Aged , Product Labeling , Surveys and Questionnaires , Young Adult
2.
Eur J Pain ; 22(3): 440-454, 2018 03.
Article in English | MEDLINE | ID: mdl-29134767

ABSTRACT

BACKGROUND: There is considerable public and political interest in the use of cannabis products for medical purposes. METHODS: The task force of the European Pain Federation (EFIC) conducted a survey with its national chapters representatives on the status of approval of all types of cannabis-based medicines, the covering of costs and the availability of a position paper of a national medical association on the use of medical cannabis for chronic pain and for symptom control in palliative/supportive care. RESULTS: Thirty-one out of 37 contacted councillors responded. Plant-derived tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray is approved for spasticity in multiple sclerosis refractory to conventional treatment in 21 EFIC chapters. Plant-derived THC (dronabinol) is approved for some palliative care conditions in four EFIC chapters. Synthetic THC analogue (nabilone) is approved for chemotherapy-associated nausea and vomiting refractory to conventional treatment in four EFIC chapters'. Eight EFIC chapters' countries have an exceptional and six chapters an expanded access programme for medical cannabis. German and Israeli pain societies recommend the use of cannabis-based medicines as third-line drug therapies for chronic pain within a multicomponent approach. Conversely, the German medical association and a team of finish experts and officials do not recommend the prescription of medical cannabis due to the lack of high-quality evidence of efficacy and the potential harms. CONCLUSIONS: There are marked differences between the countries represented in EFIC in the approval and availability of cannabis-based products for medical use. EFIC countries are encouraged to collaborate with the European Medicines Agency to publish a common document on cannabis-based medicines. SIGNIFICANCE: There are striking differences between European countries in the availability of plant-derived and synthetic cannabinoids and of medical cannabis for pain management and for symptom control in palliative care and in the covering of costs by health insurance companies or state social security systems.


Subject(s)
Antiemetics/therapeutic use , Cannabinoid Receptor Agonists/therapeutic use , Chronic Pain/drug therapy , Drug Approval/statistics & numerical data , Medical Marijuana/therapeutic use , Muscle Spasticity/drug therapy , Nausea/drug therapy , Vomiting/drug therapy , Antiemetics/supply & distribution , Antineoplastic Agents/adverse effects , Cannabidiol/supply & distribution , Cannabidiol/therapeutic use , Cannabinoid Receptor Agonists/supply & distribution , Dronabinol/analogs & derivatives , Dronabinol/supply & distribution , Dronabinol/therapeutic use , Drug Combinations , Europe , Germany , Humans , Israel , Medical Marijuana/supply & distribution , Multiple Sclerosis/complications , Muscle Spasticity/etiology , Nausea/chemically induced , Pain Management , Palliative Care , Societies, Medical , Surveys and Questionnaires , Vomiting/chemically induced
SELECTION OF CITATIONS
SEARCH DETAIL
...